NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16. An analyst at Raymond James said the stock deserves to trade at a much higher valuation.
The NGM Analyst
Steven Seedhouse initiated coverage of NGM shares with a Strong Buy and $31 price target.
The NGM Thesis
NGM has created a "sizable novel biologic pipeline," and among its pipeline candidates, aldafermin, MK-3655 and NGM621 drive Raymond James' thesis and model, Seedhouse said in a Monday initiation note. (See his track record here.)
Aldafermin, which is being evaluated in non-alcoholic steatohepatitis, or NASH, with fibrosis, seems comparable to Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) Ocaliva — the frontrunner in the NASH race — on fibrosis, but with better NASH resolution and no pruritus in a Phase 2b study, the analyst said.
See Also: Teva Analyst Says Shares Are Pricing In Too Much Risk
"Aldafermin may ultimately become the first therapy to achieve both FDA-recommended co-primary endpoints in NASH," he said.
Seedhouse said he expects the outcome of Ocaliva's June 9 AdCom to provide key insight into the potential downstream approvability/label for aldafermin in NASH.
The analyst is also bullish about MK-3655, which is a potent insulin sensitizer targeting Type 2 diabetes patients with NASH.
"Given positive results on T2DM biomarkers and liver fat reduction in Phase 1b, MK-2655 looks like a promising candidate for F0/F1 NASH with diabetes," he said.
NGM Price Action
NGM shares were trading 4.63% higher at $14.02 at the time of publication Tuesday.
Latest Ratings for NGM
|Apr 2020||Raymond James||Initiates Coverage On||Strong Buy|
View More Analyst Ratings for NGM
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes .6B Opioid Settlement
- NGM Biopharma Shares Spike Higher On Positive NASH Study Results
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.